Dr. Julie Oda, M.D
NPI: 1033538996
Total Payments
$1,336
2024 Payments
$614.58
Companies
17
Transactions
38
Medicare Patients
1,846
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$848.43 (63.5%)
Other$299.10 (22.4%)
Education$188.24 (14.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $848.43 | 33 | 63.5% |
| Long term medical supply or device loan | $299.10 | 3 | 22.4% |
| Education | $188.24 | 2 | 14.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $336.72 | 5 | $0 (2024) |
| PFIZER INC. | $154.66 | 4 | $0 (2024) |
| Lilly USA, LLC | $149.41 | 5 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $102.03 | 3 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $95.14 | 4 | $0 (2023) |
| Seattle Genetics, Inc. | $95.00 | 1 | $0 (2019) |
| Amgen Inc. | $92.87 | 3 | $0 (2023) |
| GlaxoSmithKline, LLC. | $66.18 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $44.62 | 2 | $0 (2023) |
| Mirati Therapeutics, Inc. | $41.41 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $614.58 | 16 | Novartis Pharmaceuticals Corporation ($336.72) |
| 2023 | $174.62 | 7 | Takeda Pharmaceuticals U.S.A., Inc. ($69.76) |
| 2022 | $49.62 | 2 | Pharmacyclics LLC, an AbbVie Company ($28.13) |
| 2021 | $50.82 | 2 | Pharmacyclics LLC, An AbbVie Company ($50.82) |
| 2020 | $13.46 | 1 | Lilly USA, LLC ($13.46) |
| 2019 | $95.00 | 1 | Seattle Genetics, Inc. ($95.00) |
| 2018 | $206.07 | 6 | Lilly USA, LLC ($135.95) |
| 2017 | $131.60 | 3 | PFIZER INC. ($111.68) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 09/06/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/29/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $34.57 | General |
| Category: ONCOLOGY | ||||||
| 07/02/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $12.01 | General |
| Category: Oncology | ||||||
| 05/24/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Oncology | ||||||
| 05/08/2024 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: ONCOLOGY | ||||||
| 04/30/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $20.11 | General |
| Category: Oncology | ||||||
| 04/09/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $25.61 | General |
| Category: Oncology | ||||||
| 04/01/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.57 | General |
| Category: ONCOLOGY | ||||||
| 03/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $32.27 | General |
| Category: ONCOLOGY | ||||||
| 03/22/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 02/23/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: Oncology | ||||||
| 01/22/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $33.51 | General |
| Category: ONCOLOGY | ||||||
| 01/12/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $31.61 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2023 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $42.17 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $21.34 | General |
| Category: Oncology | ||||||
| 10/02/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.28 | General |
| Category: Oncology | ||||||
| 08/29/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $27.59 | General |
| Category: ONCOLOGY | ||||||
| 08/17/2023 | Amgen Inc. | Blincyto (Biological), Kyprolis | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: Oncology | ||||||
| 06/29/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: ONCOLOGY | ||||||
| 04/07/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $28.13 | General |
| Category: ONCOLOGY | ||||||
| 03/02/2022 | EUSA Pharma (US) LLC | Sylvant (Drug) | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 548 | 13,613 | $921,131 | $382,908 |
| 2022 | 9 | 394 | 4,500 | $436,365 | $180,495 |
| 2021 | 12 | 658 | 14,396 | $1.1M | $497,352 |
| 2020 | 7 | 246 | 2,294 | $204,993 | $89,514 |
Total Patients
1,846
Total Services
34,803
Medicare Billing
$1.2M
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 20 | 4,710 | $329,460 | $142,355 | 43.2% |
| J2182 | Injection, mepolizumab, 1 mg | Office | 2023 | 11 | 4,500 | $245,000 | $104,985 | 42.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 17 | 3,480 | $147,840 | $64,546 | 43.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 60 | 298 | $42,912 | $18,927 | 44.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 61 | 96 | $24,960 | $8,607 | 34.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 71 | 104 | $27,040 | $7,117 | 26.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 42 | 42 | $16,548 | $6,138 | 37.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 38 | $13,756 | $4,571 | 33.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 67 | 86 | $15,738 | $4,554 | 28.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 32 | 41 | $14,842 | $4,344 | 29.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 24 | 40 | $10,440 | $4,250 | 40.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 48 | 55 | $10,065 | $3,808 | 37.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 26 | 26 | $10,036 | $3,080 | 30.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $6,304 | $3,012 | 47.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 11 | 37 | $4,958 | $2,081 | 42.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 22 | 44 | $1,232 | $534.64 | 43.4% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2022 | 20 | 3,810 | $247,650 | $113,612 | 45.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 129 | 223 | $80,726 | $23,303 | 28.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 44 | 194 | $27,936 | $13,136 | 47.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 56 | 86 | $31,132 | $10,941 | 35.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 23 | 39 | $10,179 | $4,422 | 43.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 19 | 19 | $7,334 | $3,374 | 46.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 21 | 21 | $8,674 | $3,097 | 35.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $6,310 | $2,570 | 40.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 26 | 28 | $7,280 | $2,260 | 31.0% |
About Dr. Julie Oda, M.D
Dr. Julie Oda, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Annapolis, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/08/2014. The National Provider Identifier (NPI) number assigned to this provider is 1033538996.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Julie Oda, M.D has received a total of $1,336 in payments from pharmaceutical and medical device companies, with $614.58 received in 2024. These payments were reported across 38 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($848.43).
As a Medicare-enrolled provider, Oda has provided services to 1,846 Medicare beneficiaries, totaling 34,803 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Hematology & Oncology
- Location Annapolis, MD
- Active Since 04/08/2014
- Last Updated 11/11/2024
- Taxonomy Code 390200000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1033538996
Products in Payments
- KISQALI (Drug) $336.72
- XTANDI (Drug) $111.68
- IMBRUVICA (Drug) $95.14
- ICLUSIG (Drug) $59.86
- OPDIVO (Biological) $44.62
- FRUZAQLA (Drug) $42.17
- KRAZATI (Drug) $41.41
- JEMPERLI (Biological) $34.57
- KEYTRUDA (Biological) $33.51
- OJJAARA (Drug) $31.61
- Enhertu (Drug) $29.57
- VERZENIO (Drug) $24.87
- PADCEV (Biological) $24.06
- Blincyto (Biological) $22.75
- Sylvant (Drug) $21.49
- ZEPZELCA (Drug) $20.89
- Perjeta (Biological) $19.92
- TIVDAK (Biological) $18.92
- CYRAMZA (Drug) $17.07
- BELEODAQ (Drug) $16.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Annapolis
Dr. Igor Belyansky, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $645,870
Student in an Organized Health Care Education/Training Program $645,870
Juddson Chason, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $20,881
Student in an Organized Health Care Education/Training Program $20,881
Mary Holthaus, Pa, PA
Student in an Organized Health Care Education/Training Program — Payments: $11,376
Student in an Organized Health Care Education/Training Program $11,376
Samip Patel, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $10,231
Student in an Organized Health Care Education/Training Program $10,231
Kari Bailey, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $6,236
Student in an Organized Health Care Education/Training Program $6,236
Sadia Shafi
Student in an Organized Health Care Education/Training Program — Payments: $4,764
Student in an Organized Health Care Education/Training Program $4,764